title: Relief of uterine bleeding by cyclic administration of dienogest for endometriosis.
abstract: OBJECTIVE
  This study assessed the relief of uterine bleeding and clinical symptoms during cyclic administration of dienogest for the treatment of endometriosis.
  
  
  METHODS
  In total, 25 patients undergoing ovarian cyst enucleation and given dienogest participated in this study. Dienogest 2 mg/day was administered for 3 weeks, and the drug was then withdrawn for 1 week (cyclic administration of dienogest). This 4-week cycle was repeated six times. Patients' records were prospectively analyzed for the number of days on which any uterine bleeding occurred, as well as menstrual pain before and after the start of dienogest administration were evaluated with a view to using the data obtained herein as the basis.
  
  
  RESULTS
  During the period of cyclic administration of dienogest, uterine bleeding occurred on 5.8 to 7.7 days per 4-week period on an average through cycles. Of uterine bleeding episodes, menstruation-like uterine bleeding was present in about 80% of patients. The visual analog scale (VAS) value for menstrual pain significantly decreased from 3.8 before dienogest administration after surgery to 1.5 at the completion of cycle 1, VAS remained low thereafter.
  
  
  CONCLUSIONS
  These results raise the possibility that cyclic administration of dienogest may relieve lessen uterine bleeding, a major adverse event and menstrual pain.
authors: Department of Obstetrics and Gynecology, Niigata City General Hospital , Niigata , Japan.
authors: Toru
authors: T
authors: Yanase
authors: Ikunosuke
authors: I
authors: Tsuneki
authors: Masaki
authors: M
authors: Tamura
authors: Takumi
authors: T
authors: Kurabayashi
mesh_terms: D000328:Adult; D004334:Drug Administration Schedule; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010049:Ovarian Diseases / Q000188:drug therapy*; D016896:Treatment Outcome; D014592:Uterine Hemorrhage / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D006727:Hormone Antagonists; C023635:dienogest; D009277:Nandrolone
keywords: Cyclic administration; dienogest; drug adherence; endometriosis; lessen uterine bleeding